Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan

Piramal Pharma Solutions is investing $90M to expand two of its U.S. facilities, adding commercial-scale manufacturing capabilities and significantly enhancing the capacity and efficiency of each site. Both facilities undergoing expansions are essential components of Piramal Pharma's integrated antibody-drug conjugate (ADC) offering, ADCelerate™, reflecting the company's commitment to delivering innovative solutions that align with patient needs. Piramal Pharma celebrated the groundbreaking of the expansion of its sterile injectables development and manufacturing facility on June 25, 2025.View original content:https://www.prnewswire.co.uk/news-releases/piramal-pharma-solutions-breaks-ground-on-90m-expansion-plan-302494244.html

en | boerse | 67931107 |